Registro de Citas
Cita APA (7a ed.)
Russell-Smith, A., Murphy, L., Nguyen, A., Blauer-Peterson, C., Terpenning, M., Cao, F., . . . Shah, R. (2023). Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting. Becaris Publishing Limited.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita Chicago Style (17a ed.)
Russell-Smith, Alexander, et al. Real-world Use of Inotuzumab Ozogamicin Is Associated with Lower Health Care Costs than Blinatumomab in Patients with Acute Lymphoblastic Leukemia in the First Relapsed/refractory Setting. Becaris Publishing Limited, 2023.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita MLA (9a ed.)
Russell-Smith, Alexander, et al. Real-world Use of Inotuzumab Ozogamicin Is Associated with Lower Health Care Costs than Blinatumomab in Patients with Acute Lymphoblastic Leukemia in the First Relapsed/refractory Setting. Becaris Publishing Limited, 2023.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Precaución: Estas citas no son 100% exactas.